Regulatory powerhouse NDA Group specializes in regulatory affairs for pharma and has a long track record exceeding 25 years, now operating as part of SSI Strategy through an acquisition. This positioning suggests potential cross-sell of regulatory optimization services to biotech startups and established companies seeking faster approvals in key markets.

Acquisition momentum SSI Strategy acquired NDA Group in August 2023, indicating strong industry validation and potential access to SSI’s client base and broader service suite. Cross-sell opportunities exist to offer combined regulatory, clinical development, medical affairs, and commercial planning services.

Leadership and advisory reach Recent hires and advisory board expansions in 2022-2023 (CFO, oncology experts, internal medicine/haematology specialists) demonstrate a broadened leadership and scientific depth. This can be leveraged to secure partnerships with mid-to-late-stage biotech firms seeking experienced governance and strategic advisory as part of a growth plan.

Global market access With a global network and emphasis on securing timely approvals across markets, there are opportunities to target biotechs aiming to enter new geographies, especially in Nordic and European regions where NDA previously launched accelerator services, indicating familiarity with regional regulatory nuances.

Financial health cue Reported revenue in the $25M–$50M range positions NDA as a mid-sized specialty firm, suggesting a need for scalable, cost-efficient solutions and partnerships that can expand project scopes without disproportionate overhead, suitable for enterprise partnerships and long-term engagements.